1. Technical Field
The present disclosure relates to devices for attaching two tubular tissues. More particularly, seals for use in connection with anastomosis procedures are described.
2. Background of Related Art
One method for performing a gastrointestinal anastomosis involves the use of a circular stapler apparatus. For example, a device known as the CEEA® (trademark of United States Surgical, a division of Tyco Healthcare Group LP) is utilized after resection of a diseased portion of bowel. The circular anastomosis stapler is utilized to approximate the remaining portions of bowel, staple them together, and cut away excess tissue at the anastomotic joint.
Illustrative circular stapling devices are disclosed in certain embodiments of U.S. patent application Ser. Nos. 4,354,628; 5,014,899; 5,040,715; and 5,392,979 the disclosures of which are hereby incorporated herein in their entirety by this reference. Other methods of performing anastomoses, utilizing joining techniques other than stapling that have been contemplated include, for example the use of clip appliers, dissectors and shears, and adhesives.
While present anastomosis devices and procedures perform satisfactorily, it would be advantageous to promote tissue growth and good sealing at an anastomosis site.
A composite seal element for use in anastomosis is described herein. The seal element can be disposed between the two portions of tubular tissue to be joined to promote tissue growth and reduce the occurrence of leaks. In stapled anastomoses, the seal element is disposed between the proximal and distal ends of an anastomosis before the tissue is approximated and staples are fired. The seal element remains in place during the healing process and then, in certain embodiments is absorbed by the body.
One aspect of the present disclosure is a seal element for sealing between tissue lumens, comprising a first material and a second material. The first material comprises a porous material for allowing tissue ingrowth. The second material comprises a sealant.
In embodiments, the second material comprises a compressible material that, when compressed between a first tissue lumen and a second tissue lumen, acts as a seal to prevent the escape of the contents of the tissue lumens. Preferably, the first material and the second material are biodegradable, bioabsorbable, or bioresorbable materials.
In certain embodiments, the seal element comprises an annular element and the second material is disposed outwardly of the first material. The first and second materials may be adhered to one another, with a biocompatible adhesive, or joined utilizing an overmolding process.
Another aspect of the present disclosure is an assembly for disposing a seal element between tissue lumens comprising a circular surgical stapling device, having an anvil assembly and a tubular body portion, the anvil assembly having an anvil member and a first shaft, the tubular body portion carrying a plurality of surgical staples in a circular configuration, the tubular body portion having a second shaft disposed inwardly of the surgical staples, the first shaft being attachable to the second shaft. The assembly includes a seal element comprising a first material and a second material. The first material comprises a porous material for allowing tissue ingrowth. The second material comprises a sealant.
Preferably, the second material comprises a compressible material that, when compressed between a first tissue lumen and a second tissue lumen, acts as a seal to prevent the escape of the contents of the tissue lumens. Preferably, the first material and the second material are biodegradable, bioabsorbable, or bioresorbable materials.
The seal element desirably has a generally centrally located aperture for being disposed on one of the first shaft and the second shaft of the circular surgical stapling device.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the disclosure and, together with a general description of the disclosure given above and the detailed description of the embodiments given below, serve to explain the principles of the disclosure, wherein:
As shown in
In certain embodiments, the first material 12 can be relatively thin (compared to the second material) and optionally is a bioabsorbable material that promotes tissue ingrowth. In certain preferred embodiments, first material 12 can be about 0.010″ to about 0.020″ thick, although other thicknesses can be used. As those skilled in the art will appreciate, tissue ingrowth is promoted more readily by materials having pores formed therein. Thus, for example, first material 12 can be any biocompatible, optionally bioabsorbable porous material, such as, for example, a foam, a mesh, a non-woven structure, or a perforated sheet. In certain preferred embodiments, first material 12 has pores in the range of about 50 μm to about 200 μm. Illustrative examples of suitable bioabsorbable porous materials include an absorbable hernia mesh such as Dexon, an absorbable felt such as Polysorb, or a porous open-cell foam such as polyurethane, suitable homopolymers, glycolide, lactide, caprolactone, trimethylene carbonate, dioxanone, polyalkylene oxides, etc. Other suitable materials are disclosed in certain embodiments of U.S. Pat. Nos. 4,655,221; 4,788,979; 5,543,218; 5,716,376; 5,423,859; and 5,124,103, the disclosures of which are hereby incorporated herein in their entirety by this reference. Without being limited to a particular theory of operation, there is a considerable amount of healing that takes place in this region. Therefore, this material is desirably porous enough to allow tissue to grow through it.
The second material 14 desirably forms a seal. Thus, second material 14 can be, for example, either a compressible or expandable optionally bioabsorbable material. In use, compressible second materials 14, when compressed, act as a seal to prevent the escape of fluid from the connected tubular tissue. In some embodiments, second material 14 is a soft, compliant material that is compressed between the proximal 16 and distal ends 18 of the anastomosis and captured by staples 33, 35. See, e.g.,
For expandable second materials 14, the material may expand in response to contact with fluids, such as the fluids naturally present in the body. In embodiments, second material 14 can be a de-hydrated material that swells upon contact with moisture. For example, second material 14 can be a hydrophilic biomaterial. Illustrative examples of suitable hydrophilic biomaterials include, but are not limited to polymers formed from one or more of the following monomers: methacrylic acid, acrylic acid, n-vinyl pyrrolidone, potassium sulfopropyl acrylate, potassium sulfopropyl methacrylate, acrylamide, dimethylacrylamide, 2-methacryloyloxyethyl phosphorylcholine, 2-hydroxyethyl methacrylate or similar biocompatible water-soluble vinyl monomers. In a particularly useful embodiment, second material 14 is formed of poly(2-hydroxyethyl methacrylate). Where seal element 10 includes a hydrophilic biomaterial as second material 14, seal element 10 can be prepared using techniques within the purview of those skilled in the art. For example, the seal element can be formed by filling a mold with a composition containing the monomer(s) and, if desired or necessary, initiator, crosslinker, plasticizer and/or biological agent, and polymerizing the composition within the mold. The choice of particular initiators, crosslinkers, etc. will be determined by the specific choice of monomer(s) and can be readily determined by those skilled in the art. A particularly useful hydrophilic biomaterial is poly(2-hydroxyethyl methacrylate) (“PHEMA”). The equilibrium water content (EWC), swelling, and mechanical properties of the PHEMA portion of seal element 10 can be controlled by crosslink density (e.g., the crosslink density can be controlled by radiation conditions or crosslinking agent, such as di(ethylene glycol) dimethacrylate (DEGDMA), concentration). The thickness of the seal element 10 is controlled by the volume of the monomer composition polymerized in the mold. The PHEMA portion of seal element 10 can also be surface modified following formation. For example, the PHEMA portion of seal element 10 can be surface modified with polymeric phospholipids for improved hemocompatibility and tissue interaction using gamma radiation grafting.
In embodiments, the surface of the portion of the seal element made from second material 14 can be patterned or templated in the nano-meso-micro scale to accommodate preferential tissue interaction at the tissue/seal interface. Such architecture or patterns can prevent or minimize post-operative tissue adhesions and superfluous collagen deposition, but afford desired mechanical and biophysical support for wound healing.
Either or both of first material 12 and second material 14 from which seal element 10 is made may also contain one or more medically and/or surgically useful substances such as drugs, enzymes, growth factors, peptides, proteins, dyes, diagnostic agents or hemostasis agents or any other pharmaceutical used in the prevention of stenosis. Non-limiting examples of suitable medically and/or surgically useful substances include: antimicrobials, antibiotics, anti-fungals, anti-virals, monoclonal antibodies, polyclonal antibodies, antimicrobial proteins/peptides (whole and fragments), enzymes, gene therapy, viral particles, chemotherapeutics, anti-inflammatories, NSAIDS, steroids, telomerase inhibitors, growth factors (TGF family, interleukin superfamily, fibroblast derived GFs, macrophage derived GFs, etc.), extracellular matrix molecules (laminin, thrombospondin, collagen, fibronectin, synthetic ECM, etc.), cell adhesion molecules, polysaccharides (hyaluronic acid, carboxymethyl cellulose, alginate, sulfonated dextran, heparin sulfate, chitosan, etc.) and others. These agents can be incorporated in situ into either or both of first material 12 and second material 14 from which seal element 10 is made or post loaded onto seal element 10 using techniques within the purview of those skilled in the art. For example, the medically and/or surgically useful substances can be freely mixed or loaded, electronically or ionically bound, covalently immobilized, chelated, or encapsulated in particles, micelles, aggregates, or any nano-meso-micro solids of varied dimension, shape morphology and dispersion/suspension ability.
Second material 14 can be attached to first material 12 in any manner within the purview of those skilled in the art, including, but not limited to an overmolding process.
Seal element 10 desirably has a generally centrally located aperture 15 for being disposed on one of the first shaft and the second shaft of a circular surgical stapling device. The seal element is captured between the proximal and distal ends of a circular, stapled anastomosis to reduce leaks at the site of anastomosis.
The dimensions of seal element 10 may vary, according to the particular application. In certain embodiments, the outside diameter is slightly larger than the diameter of the outside staple row of the circular stapling apparatus. The inside diameter will be slightly larger than the diameter of the knife of the circular stapling apparatus. Preferably, the inside diameter may be about the size of shaft 38 of anvil assembly 40 in order to center seal element 10 on the anvil assembly 40.
Referring now to
Staple cartridge assembly 32 may be fixedly connected to the distal end of tubular body portion 30 or may be configured to concentrically fit within the distal end of tubular body portion 30. Typically, staple cartridge assembly 32 includes a staple pusher (not shown) including a proximal portion having a generally frusto-conical shape and a distal portion defining two concentric rings of peripherally spaced fingers (not shown), each one of which is received within a respective staple receiving slot 46.
Typically, a knife (not shown), substantially in the form of an open cup with the rim thereof defining a knife edge, is disposed within staple cartridge assembly 32 and mounted to a distal surface of a staple pusher (not shown). The knife edge is disposed radially inward of the pair of annular arrays of staples. Accordingly, in use, as the staple pusher is advanced, the knife is also advanced axially outward.
Reference may be made to U.S. Pat. No. 5,915,616 to Viola et al., the entire content of which is incorporated herein by reference, for a detailed discussion of a suitable annular stapling device. Although the stapling device shown in
Turning now to
According to one method, as seen in
As seen in
While several particular forms of the seal elements have been illustrated and described, it will also be apparent that various modifications can be made without departing from the spirit and scope of the present disclosure. For example, it is envisioned hat each of the seal elements described herein may be used with an annular surgical anastomosing device, not including any staples for securing tissue together, which is capable of approximating, adhering and cutting tissue. Thus, it should be understood that various changes in form, detail and application of the support structures of the present disclosure may be made without departing from the spirit and scope of the present disclosure.
The present application claims the benefit of and priority to U.S. Provisional Application Ser. No. 60/619,238, filed on Oct. 15, 2004, the entire disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3054406 | Usher | Sep 1962 | A |
3124136 | Usher | Mar 1964 | A |
4347847 | Usher | Sep 1982 | A |
4354628 | Green | Oct 1982 | A |
4452245 | Usher | Jun 1984 | A |
4605730 | Shalaby et al. | Aug 1986 | A |
4655221 | Devereux | Apr 1987 | A |
4788979 | Jarrett et al. | Dec 1988 | A |
4834090 | Moore | May 1989 | A |
4838884 | Dumican et al. | Jun 1989 | A |
4930674 | Barak | Jun 1990 | A |
5002551 | Linsky et al. | Mar 1991 | A |
5014899 | Presty et al. | May 1991 | A |
5040715 | Green et al. | Aug 1991 | A |
5065929 | Schulze et al. | Nov 1991 | A |
5124103 | Kaplan et al. | Jun 1992 | A |
5222963 | Brinkerhoff et al. | Jun 1993 | A |
5263629 | Trumbull et al. | Nov 1993 | A |
5314471 | Brauker et al. | May 1994 | A |
5344454 | Clarke et al. | Sep 1994 | A |
5392979 | Green et al. | Feb 1995 | A |
5397324 | Carroll et al. | Mar 1995 | A |
5423859 | Koyfman et al. | Jun 1995 | A |
5425745 | Green et al. | Jun 1995 | A |
5441193 | Gravener | Aug 1995 | A |
5468253 | Bezwada et al. | Nov 1995 | A |
5503638 | Cooper et al. | Apr 1996 | A |
5542594 | McKean et al. | Aug 1996 | A |
5543218 | Bennett et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5575803 | Cooper et al. | Nov 1996 | A |
5653756 | Clarke et al. | Aug 1997 | A |
5683809 | Freeman et al. | Nov 1997 | A |
5690675 | Sawyer et al. | Nov 1997 | A |
5702409 | Rayburn et al. | Dec 1997 | A |
5716376 | Roby et al. | Feb 1998 | A |
5752965 | Francis et al. | May 1998 | A |
5766188 | Igaki | Jun 1998 | A |
5769892 | Kingwell | Jun 1998 | A |
5782396 | Mastri et al. | Jul 1998 | A |
5799857 | Robertson et al. | Sep 1998 | A |
5810855 | Rayburn et al. | Sep 1998 | A |
5814057 | Oi et al. | Sep 1998 | A |
5833695 | Yoon | Nov 1998 | A |
5843096 | Igaki et al. | Dec 1998 | A |
5895415 | Chow et al. | Apr 1999 | A |
5902312 | Frater et al. | May 1999 | A |
5908427 | McKean et al. | Jun 1999 | A |
5915616 | Viola et al. | Jun 1999 | A |
5931847 | Bittner et al. | Aug 1999 | A |
5964774 | McKean et al. | Oct 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6019791 | Wood | Feb 2000 | A |
6032849 | Mastri et al. | Mar 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6063097 | Oi et al. | May 2000 | A |
6080169 | Turtel | Jun 2000 | A |
6099551 | Gabbay | Aug 2000 | A |
6149667 | Hovland et al. | Nov 2000 | A |
6155265 | Hammerslag | Dec 2000 | A |
6165185 | Shennib et al. | Dec 2000 | A |
6210439 | Firmin et al. | Apr 2001 | B1 |
6214020 | Mulhauser et al. | Apr 2001 | B1 |
6258107 | Balazs et al. | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6273897 | Dalessandro et al. | Aug 2001 | B1 |
6280453 | Kugel et al. | Aug 2001 | B1 |
6299631 | Shalaby | Oct 2001 | B1 |
6312457 | DiMatteo et al. | Nov 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6325810 | Hamilton et al. | Dec 2001 | B1 |
6436030 | Rehil | Aug 2002 | B2 |
6454780 | Wallace | Sep 2002 | B1 |
6461368 | Fogarty et al. | Oct 2002 | B2 |
6503257 | Grant et al. | Jan 2003 | B2 |
6503259 | Huxel et al. | Jan 2003 | B2 |
6514283 | DiMatteo et al. | Feb 2003 | B2 |
6517566 | Hovland et al. | Feb 2003 | B1 |
6551356 | Rousseau | Apr 2003 | B2 |
6592597 | Grant et al. | Jul 2003 | B2 |
6638285 | Gabbay | Oct 2003 | B2 |
6652594 | Francis et al. | Nov 2003 | B2 |
6656193 | Grant et al. | Dec 2003 | B2 |
6669735 | Pelissier | Dec 2003 | B1 |
6677258 | Carroll et al. | Jan 2004 | B2 |
6685714 | Rousseau | Feb 2004 | B2 |
6704210 | Myers | Mar 2004 | B1 |
6723114 | Shalaby | Apr 2004 | B2 |
6726706 | Dominguez | Apr 2004 | B2 |
6736823 | Darois et al. | May 2004 | B2 |
6736854 | Vadurro et al. | May 2004 | B2 |
6746458 | Cloud | Jun 2004 | B1 |
6773458 | Brauker et al. | Aug 2004 | B1 |
6927315 | Heinecke et al. | Aug 2005 | B1 |
20020016626 | DiMatteo et al. | Feb 2002 | A1 |
20020019187 | Carroll et al. | Feb 2002 | A1 |
20020052622 | Rousseau | May 2002 | A1 |
20020091397 | Chen | Jul 2002 | A1 |
20020133236 | Rousseau | Sep 2002 | A1 |
20020138152 | Francis et al. | Sep 2002 | A1 |
20020151911 | Gabbay | Oct 2002 | A1 |
20020165559 | Grant et al. | Nov 2002 | A1 |
20020165562 | Grant et al. | Nov 2002 | A1 |
20020165563 | Grant et al. | Nov 2002 | A1 |
20030065345 | Weadock | Apr 2003 | A1 |
20030065346 | Evens et al. | Apr 2003 | A1 |
20030083676 | Wallace | May 2003 | A1 |
20030105510 | DiMatteo et al. | Jun 2003 | A1 |
20030114866 | Ulmsten et al. | Jun 2003 | A1 |
20030167064 | Whayne | Sep 2003 | A1 |
20030181927 | Wallace | Sep 2003 | A1 |
20030183671 | Mooradian et al. | Oct 2003 | A1 |
20040034377 | Sharkawy et al. | Feb 2004 | A1 |
20040092960 | Abrams et al. | May 2004 | A1 |
20040093029 | Zubik et al. | May 2004 | A1 |
20040107006 | Francis et al. | Jun 2004 | A1 |
20040116945 | Sharkawy et al. | Jun 2004 | A1 |
20040142621 | Carroll et al. | Jul 2004 | A1 |
20040172048 | Browning | Sep 2004 | A1 |
20040209059 | Foss | Oct 2004 | A1 |
20040215214 | Crews et al. | Oct 2004 | A1 |
20040215219 | Eldridge et al. | Oct 2004 | A1 |
20040215221 | Suyker et al. | Oct 2004 | A1 |
20040254590 | Hoffman et al. | Dec 2004 | A1 |
20040260315 | Dell et al. | Dec 2004 | A1 |
20050002981 | Lahtinen et al. | Jan 2005 | A1 |
20050021026 | Baily | Jan 2005 | A1 |
20050021053 | Heinrich | Jan 2005 | A1 |
20050021085 | Abrams et al. | Jan 2005 | A1 |
20050059996 | Bauman et al. | Mar 2005 | A1 |
20050059997 | Bauman et al. | Mar 2005 | A1 |
20050118435 | DeLucia et al. | Jun 2005 | A1 |
Number | Date | Country |
---|---|---|
199 24 311 | Nov 2000 | DE |
1 256 317 | Nov 2002 | EP |
WO 03105698 | Dec 2003 | WO |
Entry |
---|
International Search Report for PCT/US05/35120 date of completion is May 6, 2008 (10 pages). |
European Search Report for EP 05803193.1-2310 date of completion is Feb. 9, 2010 (3 pages). |
Number | Date | Country | |
---|---|---|---|
20060085030 A1 | Apr 2006 | US |
Number | Date | Country | |
---|---|---|---|
60619238 | Oct 2004 | US |